Update on prevention of malaria for travelers

JAMA

Volumn 278, Issue 21, 1997, Pages 1767-1771

  Lobel, Hans O ^a,c   Kozarsky, Phyllis E ^b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DOXYCYCLINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL;

ARTICLE; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION PREVENTION; MALARIA; NAUSEA; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRAVEL; VAGINITIS;

EID: 0030704256     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.21.1767     Document Type: Article

References (63)

1. Behrens RH, Curtis CF. Malaria in travellers: epidemiology and prevention. Br Med Bull. 1993; 49:363-381.
2. Hoffman SL. Diagnosis, treatment and prevention of malaria. Med Clin North Am. 1992;76:1327-1355.
3. Greenberg AE, Lobel HO. Mortality from Plasmodium falciparum malaria in travelers from the United States, 1959 to 1987. Ann Intern Med. 1990; 113:326-327.
4. Centers for Disease Control and Prevention. Health Information for International Travel 1996-97. Atlanta, Ga: Centers for Disease Control and Prevention; 1997.
5. World Health Organization. International Travel and Health: Vaccination Certificate Requirements and Health Advice, 1997. Geneva, Switzerland: World Health Organization; 1997.
6. Lobel HO, Kozarsky PE, Barber AM, Blass M, Waterman SH, Campbell CC. Pre-travel health advice to international travelers by primary care physicians. In: Program and abstracts of the 42nd annual meeting of the American Society of Tropical Medicine and Hygiene; October 31-November 4, 1993; Atlanta, Ga. Abstract 274.
7. Keystone JS, Dismukes R, Sawyer L, Kozarsky PE. Inadequacies in health recommendations provided for international travelers by North American travel health advisors. J Trav Med. 1994;1:72-78.
8. Held TK, Weinke T, Mansmann U, Trautmann M, Pohle HD. Malaria prophylaxis: identifying risk groups for noncompliance. QJM. 1994;87:17-22.
9. Peragallo MS, Cali G, Sarnicola G. Tolerance of long-term malaria chemoprophylaxis with chloroquine plus proguanil and with mefloquine among Italian troops deployed in Somalia and Mozambique. In: Program and abstracts of the Fifth International Conference on Travel Medicine; March 24-27, 1997; Geneva, Switzerland. Abstract 175.
10. Lobel HO, Phillips-Howard PA, Brandling-Bennett AD, et al. Malaria incidence and prevention among European and North American travelers to Kenya. Bull World Health Organ. 1990;68:209-215.
11. Tsai TF. Arboviral infections: general considerations for prevention, diagnosis, and treatment in travelers. Semin Pediatr Infect Dis. 1992;3(1):62-69.
12. Are insect repellents safe? Lancet. 1988;2:610-611. Editorial.
13. Lobel HO, Campbell CC. Malaria prophylaxis and distribution of drug resistance. In: Strickland GT, ed. Clinics in Tropical Medicine and Communicable Diseases. London, England: WB Saunders Co; 1986;1:225-242.
14. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg. 1992;86:121-122.
15. Than M, Kyaw MP, Soe AY, Gyi KK, Sabai M, Oo M. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg. 1995;89:307-308.
16. Schwartz IK, Lackritz EM, Patchen LC. Chloroquine-resistant Plasmodium vivax from Indonesia. N Engl J Med. 1991;324:927.
17. Wyler DJ. Malaria chemoprophylaxis for the traveler. N Engl J Med. 1993;329:31-37.
18. Lampe AS, Bakker RB, Smith SJ. Dangers of antimalarial standby treatment. Eur J Clin Microbiol Infect Dis. 1994;13:332.
19. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet. 1993;341:1299-1303.
20. Lobel HO, Miani M, Eng T, Bernard KW, High-tower AW, Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. Lancet. 1993;341: 848-851.
21. Ohrt C, Richie TL, Widjaja H, et al. A double-blind placebo-controlled trial of mefloquine versus doxycycline for the prophylaxis of malaria in Indonesian soldiers. Ann Intern Med. 1997;126:963-972.
22. Choo V. Uncertainty about mefloquine will take time to resolve. Lancet. 1996;347:891.
23. Cook G. Malaria prophylaxis: mefloquine toxicity should limit its use to treatment alone. BMJ. 1995;311:190-191.
24. Winstanley P. Mefloquine: the benefits outweigh the risks. Br J Clin Pharmacol. 1996;42:411-413.
25. Croft AMJ, World MJ. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet. 1996;347:326.
26. Regier DA, Kaelber CT. The epidemiologic catchment area (ECA) program: studying the prevalence and incidence of psychopathology. In: Tsuang MT, Tohen M, Zahner GEP, eds. Textbook in Psychiatric Epidemiology. New York, NY: Wiley-Liss; 1995:135-155.
27. Hauser WA, Annegers JF, Anderson VE. Epidemiology and genesis of epilepsy. In: Ward AA, Penry JK, Purpura D, et al, eds. Epilepsy. New York, NY: Raven Press; 1983:267-294.
28. Vuurman EFPM, Muntjewerff ND, Uiterwijk MMC, et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol. 1996;50:475-482.
29. Davis TME, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol. 1996;42: 415-421.
30. Schlagenhauf P, Lobel HO, Steffen R, et al. Tolerability of mefloquine in Swissair trainee pilots. Am J Trop Med Hyg. 1997;56:235-240.
31. MacPherson D, Gamble K, Tessier D, et al. Mefloquine tolerance-randomized, double-blinded, placebo-controlled study using a loading dose of mefloquine in pre-exposed travelers. In: Program and abstracts of the Fifth International Conference on Travel Medicine; March 24-27, 1997; Geneva, Switzerland. Abstract 220.
32. Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis. 1994;169:595-603.
33. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasit. 1993;44:257-265.
34. Arthur JD, Shanks GD, Echeverria P. Mefloquine prophylaxis. Lancet. 1990;1:972.
35. Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg. 1990;43:608-613.
36. Croft AMJ, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg. 1997;91:199-203.
37. Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996;55:50-56.
38. Huzly D, Schonfeld C, Beuerle W, et al. Malaria chemoprophylaxis in German tourists: a prospective study on compliance and adverse reactions. J Travel Med. 1996;3:148-155.
39. Wallace MR, Sharp TW, Smoak B, et al. Malaria among United States troops in Somalia. Am J Med. 1996;100:49-55.
40. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ. 1996;313:525-528.
41. Hopperus Buma APCC, van Thiel PPAM, Lobel HO, et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch Marines in Cambodia. J Infect Dis. 1996;173:1506-1509.
42. Jaspers CAJJ, Hopperus Buma APCC, van Thiel PPAM, et al. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg. 1996;55:230-234.
43. Takeshima S. Side effects with mefloquine for long-term malaria prophylaxis. Jpn J Trop Med Hyg. 1994;22:185-192.
44. Pennie RA, Koren G, Crevoisier C. Steady state pharmacokinetics of mefloquine in long-term travellers. Trans R Soc Trop Med Hyg. 1993;87:459-462.
45. Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White N. Mefloquine in infants and young children. Ann Trop Paediatr. 1996;16:281-286.
46. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf. 1996;14: 131-145.
47. Balocco R, Bonati M. Mefloquine prophylaxis against malaria for female travelers of childbearing age. Lancet. 1992;340:309-310.
48. Smoak BL, Writer JV, Keep LW, et al. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army service women. J Infect Dis. 1997;176:831-833.
49. Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic Lariam use in pregnancy. Am J Trop Med Hyg. In press.
50. Shanks GD. The rise and fall of mefloquine as an antimalarial drug in South East Asia. Mil Med. 1994; 159:275-281.
51. Brasseur P, Kouamouo J, Moyou-Somo K, Druilhe P. Multi-drug resistant falciparum malaria in Cameroon 1987-88. Am J Trop Med Hyg. 1992; 46:8-14.
52. Lobel HO, Varma JK, Miani M, et al. Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: implications for travelers' health. Am J Trop Med Hyg. In press.
53. Pang LW, Limsomwong N, Boudreau EF. Doxycycline prophylaxis for falciparum malaria. Lancet. 1987;1:1161-1164.
54. Singharaj P, Eamsila C, Bhothisuwan A. Efficacy of doxycycline on malaria prophylaxis in the soldiers deployed to the Thai-Kampuchean border. R Thai Army Med J. 1987;40:165-171.
55. Watanasook C, Singharaj P, Surlyamongkol V, et al. Malaria prophylaxis with doxycycline in soldiers deployed to the Thai-Kampuchean border. Southeast Asian J Trop Med Public Health. 1989; 20:61-64.
56. Delaney TJ, Leppard BJ, MacDonald DM. Effects of long term treatment with tetracycline. Acta Derm Venereol (Stockh). 1974;54:487-489.
57. Fish DR, Espir MLE. Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy. BMJ. 1988;297:526-527.
58. Lovestone S. Chloroquine-induced mania. Br J Psych. 1991;159:164-165.
59. Bruce-Chwatt LJ, Bruce-Chwatt JM. Antimalarial drugs in West Africa, with particular reference to proguanil. BMJ 1950;2:7-14.
60. Shanks GD. Drugs for prophylaxis and treatment of malaria. J Travel Med. 1994;1:40-47.
61. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996; 55:243-249.
62. Bernard KW, Smith PW, Kader FJ, Moran MJ. Neuroparalytic illness and human diploid cell rabies vaccine. JAMA. 1982;248:3136-3138.
63. Creagh TH. The use of cohort studies in pharmacoepidemiology. In: Strom BL, Velo G, eds. Drug Epidemiology and Post-Marketing Surveillance. New York, NY: Plenum Publishing Corp; 1992:53-58.